Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.
paper
Cited
Public
Unavailable
- Authors
- Ramesh, Divya; Gamage, Thomas F; Vanuytsel, Tim; Owens, Robert A; Abdullah, Rehab A; Niphakis, Micah J; Shea-Donohue, Terez; Cravatt, Benjamin F; Lichtman, Aron H
- Year
- 2013
- Journal
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
- PMID
- 23303065
- DOI
- 10.1038/npp.2012.269
- PMCID
- PMC3629394
Inhibition of the endocannabinoid catabolic enzymes, monoacylglycerol lipase (MAGL) or fatty acid amide hydrolase (FAAH) attenuates naloxone-precipitated opioid withdrawal signs in mice via activation of CB1 receptors. Complete FAAH inhibition blocks only a subset of withdrawal signs, whereas complete MAGL inhibition elicits enhanced antiwithdrawal efficacy, but is accompanied with some cannabimimetic side effects. Thus, the primary objective of the present study was to determine whether combined, full FAAH inhibition and partial MAGL represents an optimal strategy to reduce opioid withdrawal. To test this hypothesis, we examined whether combined administration of high-dose of the FAAH inhibitor PF-3845 and low-dose of the MAGL inhibitor JZL184, as well as the novel dual FAAH-MAGL inhibitor SA-57, which is 100-fold more potent in inhibiting FAAH than MAGL, would prevent spontaneous withdrawal in morphine-dependent mice, a model with greater face validity than precipitating withdrawal with ΞΌ-opioid receptor antagonists. Strikingly, a combination of low-dose JZL184 and high-dose PF-3845 as well as the dual inhibitor SA-57 reduced all abrupt withdrawal signs (ie, platform jumping, paw flutters, head shakes, diarrhea, and total body weight loss), but did not elicit any cannabimimetic side effects. In addition, JZL184 or PF-3845 blocked naloxone-precipitated hypersecretion in morphine-dependent small intestinal tissue. Collectively, these results are the first to show that endocannabinoid catabolic enzyme inhibitors reduce abrupt withdrawal in morpine-dependent mice and are effective in a novel in vitro model of opioid withdrawal. More generally, these findings support the idea that joint MAGL and FAAH inhibition represents a promising approach for the treatment of opioid dependence.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Endocannabinoid response to social stress in chronic non-medical prescription opioid users. | Schmid VK et al. | β | 2026 | β |
| FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders. | Maddox CJ et al. | β | 2026 | β |
| Absence of Evidence for Sustained Effects of Daily Cannabidiol Administration on Anandamide Plasma Concentration in Individuals with Cocaine Use Disorder: Exploratory Findings from a Randomized Controlled Trial. | Hebert FO et al. | β | 2025 | β |
| Mice lacking the endocannabinoid-synthesizing enzyme NAPE-PLD exhibit sex-dependent dysregulations in responsiveness to oxycodone and a natural reward. | Woodward TJ et al. | β | 2025 | β |
| Pharmacological potential of endocannabinoid and endocannabinoid-like compounds in protecting intestinal structure and metabolism under high-fat conditions. | Vari F et al. | β | 2025 | β |
| The Role of Fatty Acid Binding Proteins in Neuropsychiatric Diseases: A Narrative Review. | Powell A et al. | β | 2025 | β |
| Amyotrophic Lateral Sclerosis and Pain: A Narrative Review from Pain Assessment to Therapy. | Pota V et al. | β | 2024 | β |
| Cannabidiol Reduced the Severity of Gastrointestinal Symptoms of Opioid Withdrawal in Male and Female Mice. | Scicluna RL et al. | β | 2024 | β |
| Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. | MartΓnez-Rivera A et al. | β | 2024 | β |
| Endocannabinoid agonist 2-arachidonoylglycerol differentially alters diurnal activity and sleep during fentanyl withdrawal in male and female mice. | Gamble MC et al. | β | 2024 | β |
| Anti-nociceptive potential of an isatin-derived dual fatty acid amide hydrolase-monoacylglycerol lipase inhibitor. | Jaiswal S et al. | β | 2023 | β |
| Anxiety associated with palatable food withdrawal is reversed by the selective FAAH inhibitor PF-3845: A regional analysis of the contribution of endocannabinoid signaling machinery. | de Ceglia M et al. | β | 2023 | β |
| Sex-specific Effects of the Endocannabinoid Agonist 2-Arachidonoylglycerol on Sleep and Circadian Disruptions during Fentanyl Withdrawal | Gamble MC et al. | β | 2023 | β |
| Cannabidiol and substance use disorder: Dream or reality. | Karimi-Haghighi S et al. | β | 2022 | β |
| Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. | Papa A et al. | β | 2022 | β |
| Synthesis and evaluation of carbamate derivatives as fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. | Jaiswal S et al. | β | 2022 | β |
| The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. | Dodu JC et al. | β | 2022 | β |
| Endocannabinoid and dopaminergic system: the pas de deux underlying human motivation and behaviors. | Laksmidewi AAAP et al. | β | 2021 | β |
| Endocannabinoid modulation of dopamine release during reward seeking, interval timing, and avoidance. | Everett TJ et al. | β | 2021 | β |
| On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence. | Paredes-Ruiz KJ et al. | β | 2021 | β |
| The protective effect of JZL184 on ovarian ischemia reperfusion injury and ovarian reserve in rats. | Demir Γaltekin M et al. | β | 2021 | β |
| Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation. | Butler K et al. | β | 2020 | β |
| Positive Allosteric Modulation of CB<sub>1</sub> Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. | Slivicki RA et al. | β | 2020 | β |
| The impact of naturalistic cannabis use on self-reported opioid withdrawal. | Bergeria CL et al. | β | 2020 | β |
| The role of catecholamines in modulating responses to stress: Sex-specific patterns, implications, and therapeutic potential for post-traumatic stress disorder and opiate withdrawal. | Ross JA et al. | β | 2020 | β |
| Brain activity of anandamide: a rewarding bliss? | Scherma M et al. | β | 2019 | β |
| Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. | Dunn KE et al. | β | 2019 | β |
| Ξ<sup>9</sup>-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions. | Nguyen JD et al. | β | 2019 | β |
| Monoacylglycerol lipase (MAGL) as a promising therapeutic target. | Gil-OrdΓ³Γ±ez A et al. | β | 2018 | β |
| New approaches and challenges to targeting the endocannabinoid system. | Di Marzo V | β | 2018 | β |
| Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption. | Marcus DJ et al. | β | 2017 | β |
| Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. | Grabner GF et al. | β | 2017 | β |
| Reciprocal Catecholamine Changes during Opiate Exposure and Withdrawal. | Fox ME et al. | β | 2017 | β |
| The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. | Wilkerson JL et al. | β | 2017 | β |
| The endocannabinoid system as a target for addiction treatment: Trials and tribulations. | Sloan ME et al. | β | 2017 | β |
| Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the "weed," a pharmacodynamic discussion. | Boggs DL et al. | β | 2016 | β |
| Double Dissociation of Monoacylglycerol Lipase Inhibition and CB1 Antagonism in the Central Amygdala, Basolateral Amygdala, and the Interoceptive Insular Cortex on the Affective Properties of Acute Naloxone-Precipitated Morphine Withdrawal in Rats. | Wills KL et al. | β | 2016 | β |
| Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature. | Wills KL et al. | β | 2016 | β |
| From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. | Ligresti A et al. | β | 2016 | β |
| Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. | Lofwall MR et al. | β | 2016 | β |
| Roles for the endocannabinoid system in ethanol-motivated behavior. | Henderson-Redmond AN et al. | β | 2016 | β |
| The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. | Wilkerson JL et al. | β | 2016 | β |
| Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice. | Gamage TF et al. | β | 2015 | β |
| Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. | Befort K | β | 2015 | β |
| Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. | Carey CE et al. | β | 2015 | β |
| Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects. | Sadhasivam S et al. | β | 2015 | β |
| Repeated morphine treatment alters cannabinoid modulation of GABAergic synaptic transmission within the rat periaqueductal grey. | Wilson-Poe AR et al. | β | 2015 | β |
| Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Ξ9-tetrahydrocannabinol in mice. | Hruba L et al. | β | 2015 | β |
| The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs--A practical view. | Fowler CJ | β | 2015 | β |
| The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review. | Fowler CJ | β | 2015 | β |
| 2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. | Makriyannis A | β | 2014 | β |
| Endogenous opiates and behavior: 2013. | Bodnar RJ | β | 2014 | β |
| Neuroinflammation as a possible link between cannabinoids and addiction. | Rodrigues LC et al. | β | 2014 | β |
| Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice. | Schlosburg JE et al. | β | 2014 | β |
| Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone? | Oleson EB et al. | β | 2014 | β |
| Targeting the endogenous cannabinoid system to treat neuropathic pain. | Lau BK et al. | β | 2014 | β |